Accelerate Diagnostics
3950 S. Country Club Road
Suite 470
Tucson
Arizona
85714
United States
Tel: 520-365-3100
Fax: 520-269-6580
Website: http://acceleratediagnostics.com/
Email: contact@axdx.com
134 articles about Accelerate Diagnostics
-
Accelerate Diagnostics scheduled call to review 2022 third quarter results
10/24/2022
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, November 14, 2022, at 4:30 p.m. Eastern Time to review 2022 third quarter results.
-
Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock - Aug 19, 2022
8/19/2022
Accelerate Diagnostics, Inc. announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $2.00 per share.
-
Accelerate Diagnostics Announces Proposed Public Offering of Common Stock - Aug 17, 2022
8/17/2022
Accelerate Diagnostics, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.
-
BD, Accelerate Diagnostics Announce Global Commercial Collaboration
8/15/2022
BD and Accelerate Diagnostics, Inc. announced a worldwide commercial collaboration agreement where BD will offer Accelerate's rapid testing solution for antibiotic resistance and susceptibility offering results in hours, versus one to two days with some traditional laboratory methods.
-
Accelerate Diagnostics Reports Second Quarter 2022 Financial Results
8/15/2022
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2022.
-
Accelerate Diagnostics scheduled call to review 2022 second quarter results
7/25/2022
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, August 15, 2022, at 4:30 p.m. Eastern Time to review 2022 second quarter results.
-
Accelerate Diagnostics announces commercialization in Europe of its Accelerate Arc™ system having completed IVDR registration
7/11/2022
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, today announced CE marking of its new Accelerate Arc Module and BC kit.
-
Accelerate Diagnostics to Participate in 42nd Annual William Blair Growth Stock Conference on June 7, 2022
5/23/2022
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Chief Executive Officer, Jack Phillips, will present at the 42nd Annual William Blair Growth Stock Conference on Thursday, June 7, 2022, at 10:00 AM Central Time.
-
Accelerate Diagnostics Reports First Quarter 2022 Financial Results
5/16/2022
Accelerate Diagnostics, Inc. announced financial results for the first quarter for the period ended March 31, 2022.
-
Accelerate Diagnostics announces commercialization of its Accelerate Arc™ system having completed IVD registration with FDA
5/16/2022
Commercialization of Accelerate Arc system, which includes the Accelerate Arc Module and BC kit, unlocks the path to automated, rapid microbial ID for positive blood cultures across the large installed base of MALDI system users.
-
Accelerate Diagnostics scheduled call to review 2022 first quarter results.
4/29/2022
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, May 16, 2022, at 4:30 p.m. Eastern Time to review 2022 first quarter results.
-
Accelerate Diagnostics Presents New Data at ECCMID 2022 Demonstrating Rapid and Accurate Results Using Automated Accelerate Arc™ Module and BC Kit
4/25/2022
Accelerate Diagnostics, Inc. today announced the release of new data on the Accelerate Arc Module and BC kit at the 32nd European Congress for Clinical Microbiology and Infectious Diseases (ECCMID) located in Lisbon, Portugal 23-26 April 2022.
-
Accelerate Diagnostics Announces Launch Of Accelerate Arc™ Module and BC Kit
3/28/2022
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the launch of the Accelerate Arc system, comprised of the Arc Module and BC Kit, an automated path to rapid and accurate microbial identification for positive blood cultures.
-
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2021 Financial Results
3/8/2022
Accelerate Diagnostics, Inc. announced financial results for the fourth quarter and full year ended December 31, 2021.
-
Accelerate Diagnostics scheduled call to review 2021 fourth quarter and full year results
2/24/2022
Accelerate Diagnostics, Inc. announced that management will host a conference call on Wednesday, March 8, 2022, at 4:30 p.m. Eastern Time to review 2021 fourth quarter and full year financial results.
-
Accelerate Diagnostics to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:00 a.m. Eastern Time
2/2/2022
Accelerate Diagnostics, Inc. announced that the company is scheduled to present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:00 a.m. Eastern Time.
-
Accelerate Diagnostics Announces Preliminary Fourth Quarter & Full-Year 2021 Financial Results
1/13/2022
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the quarter and year ending December 31, 2021. Highlights for the fourth quarter and full-year 2021 are presented below.
-
Accelerate Diagnostics Wins Suzhou Innovation Award to Support Continued China Commercialization Efforts
1/12/2022
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that it was honored as a recipient of China's Suzhou Industrial Park's (SIP) 15th Science and Technology Leaders Innovation Award for the Company's Accelerate Pheno® System.
-
Accelerate Diagnostics to Participate Virtually in 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022
12/29/2021
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that the company is scheduled to present at the 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022, at 9:45a.m. Eastern.
-
New Accelerate Pheno® System Multi-Center Study Published in Clinical Infectious Diseases
11/22/2021
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the publication of its Improving Outcomes and Antibiotic Stewardship (IOAS) Study in the journal Clinical Infectious Diseases.